Valacyclovir for the treatment of genital herpes

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 367-376

  Brantley, Julie S ^a   Hicks, Lindsey ^b   Sra, Karan ^a   Tyring, Stephen K ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b EAST TEXAS MEDICAL CENTER   (United States)

Author keywords

Acyclovir; Antiviral therapy; Genital herpes; Herpes labialis; Herpes simplex virus; Herpes zoster; Valacyclovir

Indexed keywords

ACICLOVIR; ACICLOVIR TRIPHOSPHATE; ANTACID AGENT; ANTIVIRUS AGENT; CIMETIDINE; DIGOXIN; DRUG METABOLITE; FAMCICLOVIR; GANCICLOVIR; GUANOSINE DERIVATIVE; PENCICLOVIR; PLACEBO; PROBENECID; PRODRUG; THIAZIDE DIURETIC AGENT; VALACICLOVIR;

ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; GENITAL HERPES; HEADACHE; HERPES LABIALIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; NAUSEA; PATIENT COMPLIANCE; POSTHERPETIC NEURALGIA; PREVALENCE; RECURRENT DISEASE; RECURRENT INFECTION; SEXUALLY TRANSMITTED DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES; VIRUS TRANSMISSION;

ACYCLOVIR; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HERPES GENITALIS; HERPES ZOSTER; HUMANS; RECURRENCE; VALINE;

EID: 33745208008     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.367     Document Type: Article

References (50)

1. Elion GB, Furman PA, Fufe JA et al. Selectivity of action of an anti-herpetic agent, 9-[2- hydroxyethoxymethyll guanine. Proc. Natl Acad. Sci. USA 74, 5716-5720 (1997).
2. Hayden RG. Antimicrobial agents. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. Hardman JG, Limbirdeds LE (Eds), McGraw-Hill, NY, USA, 1191-1223 (1996).
3. Ormrod D, Scott LJ, Perry CM. Valacyclovir: a review of its long-term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 59, 839-863 (2000).
4. Beutner KR, Friedman DJ, Forszpaniak C et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. 39, 1546-1553 (1995).
5. Luber AD, Flaherty JF. Famciclovir for treatment of herpesvirus infections. Ann. Pharmacother. 30, 978-985 (1996).
6. Valtrex® (valacyclovir hydrochloride) product information. GlaxoSmithKline, USA, October (2005).
7. Fife KG, Crumpacker CS, Mertz GJ et al. Recurrence and resistance patterns of herpes simplex virus following cessation of at least 6 years of chronic suppression with acyclovir. J. Infect. Dis. 169, 1338-1341 (1994).
8. Kriesel JD, Spruance SL, Prichard M et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J. Infect. Dis. 192(1), 156-161 (2005).
9. Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch. Intern. Med. 163(1), 76-80 (2003).
10. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolite disposition of valacyclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39(12), 2759-2764 (1995).
11. Burpo RH. Antiviral agents in women's health: pharmacotherapeutics of treating influenza and herpes. J. Midwifery Womens Health 47(3), 182-189 (2002).
12. Fife KH, Barbarash RA, Rudolph T et al. Valacyclovir versus acyclovir in the treatment of first-episode genital herpes infection. Sex. Transm. Dis. 24, 481-486 (1997).
13. Spruance SL, Tyring SK, Degregorio B et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Amb. Intern. Med. 156, 1729-1735 (1996).
14. Tyring SK, Douglas JM, Corey L. et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch. Dermatol. 134, 185-191 (1998).
15. Bodsworth NJ, Crooks RJ, Borelli S et al. Valaciclovir versus aciclovir in patient intiated treatment of recurrent genital herpes: a randomized, double-blind clinical trial. Genitourin. Med. 73, 110-116 (1997).
16. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin. Infect. Dis. 34, 958-962 (2002).
17. Wald A, Carrell D, Remington M et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin. Infect. Dis. 34, 944-948 (2002).
18. Aoki FY, Tyring S, Diaz-Mitoma F et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 42, 8-13 (2006).
19. Pate0l R, Bodsworth NJ, Woolley P et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo-controlled study of once-daily therapy. Genitourin. Med. 73, 105-109 (1997).
20. Reitano, M, Trying S, Lang W et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus Infection: a largescale dose range-finding study. J. Infect. Dis. 178, 603-610 (1998).
21. Baker DA, Blythe JG, Miller JM. Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Obstet. Gynecol. 94, 103-106 (1999).
22. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex. Transm. Infect. 75, 398-402 (1999).
23. Romanowski B, Marina RB, Roberts JN: The Valtrex HS230017 Study Group. Patients' preference of valacyclovir once-daily supppressive therapy versus twice-daily episodic therapy for recurrent genital herpes. Sex. Transm. Dis. 30(3), 226-231 (2003).
24. Conant MA, Schacker TW, Murphy RL et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int. J. STD AIDS 13, 12-21 (2002).
25. Spruance SL, Jones TM, Blatter MM et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother. 47(3), 1072-1080 (2003).
26. Jensen LA, Hoehns JD, Squires CL. Oral antivirals for the acute treatment of recurrent herpes labialis. Ann. Pharmacother. 38(4), 705-709 (2004).
27. Wald A, Zeh J, Selke S et al. Virological characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med. 333(12), 770-775 (1995).
28. Anderson BJ. The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Clin. J. Sport Med. 9(2), 86-90 (1999).
29. Grant DM, Mauskopf JA, Bell L, Austin R. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy 17(2), 333-341 (1997).
30. Tyring SK, Beutner KR, Tucker BA et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch. Fam. Med. 9, 863-869 (2000).
31. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J. Infect. Dis. 186(Suppl. 1), S40-S46 (2002).
32. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced HIV disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 76, 369-380 (1997).
33. Chulay JD, Bell AR. Long-term safety of valaciclovir for suppression of herpes simplex virus infection [abstract 105]. Clin. Infect. Dis. 23, 879 (1996).
34. Gupta R, Wald A, Krantz E et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J. Infect. Dis. 190(8), 1374-1381 (2004).
35. Corey L, Wald A, Patel R et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 350(1), 11-20 (2004).
36. Griffiths PD. Tomorrow's challenges for herpesvirus management: potential applications of valacyclovir. J. Infect. Dis. 186(Suppl. 1), S131-S137 (2002).
37. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340, 1462-1470 (1999).
38. Sund F, Wahlberg J, Eriksson BM. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valacyclovir. J. Clin. Virol. 23, 107-111 (2001).
39. Reischig T, Opatrny K Jr, Bouda M, Treska V, Jindra P, Svecova M. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transpl. Int. 15, 615-622 (2002).
40. Fiddian P, Sabin CA, Griffiths PD. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J. Infect. Dis. 186(Suppl. 1), S110-S115 (2002).
41. Egan JJ, Carroll KB, Yonan N et al. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J. Heart Lung Transplant. 21, 460-466 (2002).
42. Malouf MA, Chhajed PN, Hopkins P et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J. Heart Lung Transplant. 21, 547-554 (2002).
43. Beeson WH, Rachel JD. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. Dermatol. Surg. 28, 331-336 (2002).
44. Bech E, Lycke J, Gadeberg P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 58, 31-36 (2002).
45. Scott LL. Prevention of perinatal herpes: prophylactic antiviral therapy? Clin. Obstet. Gynecol. 42(l), 134-148 (1999).
46. Kroon S, Whitley RJ. Management strategies in herpes: can we improve management of perinatal HSV infection? In: Management Strategies in Herpes. PPS Europe Ltd, Worthing, UK, 19-21 (1995).
47. Scott LL, Sanchez PJ, Jackson GL et al. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet. Gynecol. 87(1), 69-73 (1996).
48. Sheffield JS, Hollier LM, Hill JB et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet. Gynecol. 102(6), 1396-1403 (2003).
49. Kimberlin DF, Weller S, Andrews WW et al. Valaciclovir pharmacokinetics in late pregnancy. Am. J. Obstet. Gynecol. 178, S12 (1998).
50. Andrews WW, Kimberlin DF, Whitle R et al. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am. J. Obstet. Gynecol. 194(3), 774-781 (2006).